ARM-002TM anti-cancer vaccine shows promise in combatting pre-established melanoma
Defence Therapeutics Inc. has unveiled the exceptional efficacy of its second-generation ARMTM anti-cancer vaccine.
The anti-cancer vaccine, dubbed ARM-002TM, has demonstrated proficiency in combating pre-established...
Chiesi Group celebrates €3bn sales success in 2023
Chiesi Group, a renowned biopharmaceutical powerhouse headquartered in Parma, Italy, revealed €3bn in sales in 2023, a significant growth from the previous year.
With 31...
B Medical Systems’ TCW40SDD receives ACT label from My Green Lab
B Medical Systems, an industry leader in the medical cold chain sector, has received the prestigious ACT label from My Green Lab for its...
Defence Therapeutics announces successful ARM-002TM cancer vaccine results
Defence Therapeutics has announced the successful testing of its second-generation anti-cancer vaccine, named ARM-002TM, utilising its flagship anti-cancer molecule, AccuTOX®.
The ARM-002TM cancer vaccine, when...
Defence Therapeutics granted US patent for AccuTOX® technology
Defence Therapeutics has achieved a significant milestone with the granting of US patent no. 11,890,350 ('350) by the United States Patent and Trademark Office...
BioNxt acquires cutting-edge equipment to boost drug delivery product manufacturing
BioNxt Solutions Inc. has proudly announced the acquisition of advanced coating and cutting equipment, marking a crucial stride in expanding its commercial manufacturing of...
Defence Therapeutics’ breakthrough in cancer treatment: AccuTOX® shows promise against lung tumours
Defence Therapeutics has announced the successful testing of a new formulation of its ACCUM-002TM Dimer CDCA-SV40 against lung tumours.
Defence Therapeutics granted FDA approval for Phase I Clinical Trial of AccuTOX®
Defence Therapeutics has announced a pivotal milestone: the U.S. Food and Drug Administration (FDA) has granted a green light with a "Study May Proceed"...
Defence Therapeutics applies to use AccuTOX® as an advanced tumour treatment
Defence Therapeutics has submitted an Investigational New Drug application for AccuTOX®, an injectable anticancer molecule.
Defence Therapeutics awarded CIPO patent for vaccine technology
Defence Therapeutics has announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for the company's Canadian patent application no....
AccuTOX® anticancer drug demonstrates exciting antigen cross-presentation
Defence Therapeutics Inc., a prominent Canadian biopharmaceutical company renowned for its work in immune-oncology vaccines and drug delivery technologies, has announced the discovery of...
Administration of AccuTOX™-chitosan inhibits the growth of established solid lymphoma in animals
Defence Therapeutics has announced that systemic administration of novel AccuTOX™-chitosan encapsulated formulation inhibits the growth of pre-established solid lymphoma resulting in their progressive shrinking...
Defence Therapeutics Inc. releases Accum® study revealing its anti-cancer properties
Defence Therapeutics Inc. have announced the publication of a peer-reviewed study on the anti-cancer properties of its unconjugated Accum®.
Accum®-mRNA lipid nanoparticles have double the antibody response of traditional mRNA vaccines
Defence Therapeutics has announced a groundbreaking achievement, demonstrating that its Accum®-mRNA lipid nanoparticles elicit twice the antibody response of mRNA-based vaccines.
The company's encapsulation strategy,...
Cold chain challenges solved with collaboration
B Medical Systems has hosted a roundtable event at Medlab Asia – providing insights into the challenges of cold chain systems.
During the Medlab Asia...
How Defence’s Accum® technology is advancing cancer therapeutics
Industry-leading biotechnology pioneer Defence Therapeutics details how the company is advancing immune oncology through its revolutionary Accum® technology.
Whether using an antibody, cell-based vaccine or...
Defence Therapeutics’ biotechnology showcased on the Viewpoint with Dennis Quaid
Defence Therapeutics’ revolutionary biotechnology will feature on the television show Viewpoint with Dennis Quaid.
Hosted by veteran actor Dennis Quaid, Viewpoint is an educational television...
Zentek and McMaster announce positive results for the aptamer platform
Zentek has announced that its aptamer platform, under global license from McMaster University, has been successfully tested as a therapeutic for SARS-CoV-2 in pre-clinical...
Defence completes first milestone of Orano collaboration agreement
Defence Therapeutics Inc. has announced that it has successfully reached the first milestone established in the Orano collaboration agreement.
The collaboration agreement was entered with...
Defence Therapeutics details impressive Accum™ patent portfolio
Leading biotechnology company Defence Therapeutics explores its growing patent portfolio for the company’s flagship AccumTM-based platform.
Defence Therapeutics is harnessing the power of AccumTM to...
